Women in Control: A Virtual World Study of Diabetes Self-Management

Sponsor
Boston Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT02726425
Collaborator
University of Massachusetts, Worcester (Other), Sargent College of Health and Rehabilitation Sciences (Other), Boston University (Other), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
309
1
2
58
5.3

Study Details

Study Description

Brief Summary

This study evaluates the comparative effectiveness of a diabetes self management (DSM) group medical visit in the virtual world (Second life) verses a face-to-face format, aimed to increase physical activity and improve glucose control among Black/African American and Hispanic women with uncontrolled diabetes mellitus.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Diabetes Self Management Medical Group Visits
N/A

Detailed Description

The prevalence of diabetes mellitus (DM) in the US is disproportionately high among minority women. In order to participate as partners in healthcare, DM patients need self-management education and support. Diabetes self-management (DSM) support is effective in helping DM patients make good choices and achieve clinical goals but is difficult to deliver in medical practice settings. Virtual reality technology can assist DM patients and their clinical teams with DSM support by providing effective educational tools in an engaging, learner-centered context that fosters self-efficacy and skill proficiency. Our prior work demonstrated that virtual worlds, like Second Life (SL), are suitable for supporting DSM education for patients. SL, an Internet-based virtual world, is an example of an immersive, three-dimensional environment which supports social networking and interaction with information.

The investigators now aim to enhance the existing diabetes curriculum using a medical group visit design to study whether the Women in Control virtual world group medical visit leads to similarly effective health and educational outcomes compared to face-to-face group medical visits. The investigators aims are to conduct a randomized, controlled trial of the comparative effectiveness of a virtual world DSM group medical visit format vs. a face-to-face DSM group visit format to increase physical activity and improve glucose control among Black/African American and Hispanic women with uncontrolled DM at six month follow up, and to conduct a qualitative, ethnographic study of participant engagement with the virtual world platform during the virtual world group sessions, between group sessions, and following completion of the eight-week curriculum to characterize learners' self-directed interactions with the technology platform and assess the correlation of these interactions with DSM behaviors and diabetes control.

Study Design

Study Type:
Interventional
Actual Enrollment :
309 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Women in Control: A Virtual World Study of Diabetes Self-Management. Translational Research to Improve Diabetes and Obesity Outcomes (R01)
Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
May 1, 2020
Actual Study Completion Date :
May 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Second Life Participants

Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)

Behavioral: Diabetes Self Management Medical Group Visits
The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.

Active Comparator: Face-to-Face Participants

The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.

Behavioral: Diabetes Self Management Medical Group Visits
The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.

Outcome Measures

Primary Outcome Measures

  1. Change in physical activity level [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Participants will wear an activity monitor for a week at each collection point. Results measured in METs/hr.

  2. Change in disease control (HbA1c) [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Change in HbA1c from BMC laboratory blood testing results

Secondary Outcome Measures

  1. Patient Activation [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Measured by change in PAM 13 score

  2. Medication Adherence [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Prescription fulfillment ratio per i2b2 database claims data analysis

  3. Depression [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Change in Patient Health Questionnaire (PHQ8) score

  4. Improvement in cholesterol, hypertension and body weight [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Serum LDL/HDL from BMC laboratory results. BP from home blood pressure monitor readings. BMI from weight/height measurements.

  5. Health-Related Quality of Life [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Change in Q-LES-Q screening survey

  6. Dietary Habits [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Multiple measures of 24-hr dietary recall

  7. Functional Status [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Measured by Sheehan disability scale

  8. Stress [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Measured by perceived stress scale (PSS-10)

  9. Social Support [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Measured by MOS social support survey

  10. Health Service Utilization [Data collection at baseline, post-intervention (8 weeks) and at 6 months follow up]

    Self-report and chart review of hospitalizations, PCP and specialist visits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with type 2 diabetes mellitus (documented in the medical chart)

  • Last recorded HbA1c >8.0

  • Currently treated with diet, oral hypoglycemic agents or insulin

  • Black/African American or Hispanic/Latina origin

  • Has telephone access

  • Able to understand and participate in study protocol

  • Functionally capable of meeting the activity goals

  • Understand and give informed consent

  • Physician approval to participate in study

  • Can communicate in English or Spanish

Exclusion Criteria:
  • History of diabetic ketoacidosis

  • Currently or planning pregnancy

  • Unable or unwilling to provide informed consent

  • Plans to leave area within 6 month study period that would interfere with ability to attend 8 weekly sessions and/or 6 month follow up

  • Required intermittent glucocorticoid therapy within past 3 months.

  • Experienced acute coronary event (myocardial infarction or unsable angina) within previous 6 months

  • Medical condition that precludes adherence to study dietary recommendations (i.e. Crohn's, ulcerative colitis, etc)

  • Medical or serious psychiatric illness (dementia, suicidal within last 5 months, psychiatric hospitalization). Those with diagnosis of depression or who take antidepressents are eligible.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Boston Medical Center Boston Massachusetts United States 02118

Sponsors and Collaborators

  • Boston Medical Center
  • University of Massachusetts, Worcester
  • Sargent College of Health and Rehabilitation Sciences
  • Boston University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Suzanne E Mitchell, MD, MS, Boston Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Boston Medical Center
ClinicalTrials.gov Identifier:
NCT02726425
Other Study ID Numbers:
  • H-34220
  • 1R01DK106531
First Posted:
Apr 1, 2016
Last Update Posted:
Sep 4, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Boston Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 4, 2020